Pursuant to announcement of Board Meeting dated January 04, 2022, Gennex Laboratories has informed that 836,165 equity shares equivalent to 6.73% of Deccan Remedies (DRL) acquired from the existing promoter’s shareholders group and the share funded through internal accruals and in turn the Company will hold 51% equity shares of DRL. Further, the Company holds composition of the Board Directors and referring to the above share acquired exercises or controls more than one-half of the total voting power either at its own or together with one or more of its promoter’s shareholders group. Based on controlling position and voting power in DRL the Company will fall under Sec.2(46) of the Companies Act (CA), 2013 'Holding Company' definition and DRL shall fall 'Subsidiary Company' Definition u/Sec.2(87) of the CA, 2013.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1794.30 |
| Dr. Reddys Lab | 1275.05 |
| Cipla | 1383.00 |
| Zydus Lifesciences | 1105.65 |
| Lupin | 2274.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: